Eagle Clinical Tresos PRO HPA (Integria Healthcare Australia Pty Ltd)
Product Name
Eagle Clinical Tresos PRO HPA
ARTG
393596
Date of review outcome
Date of publication
Mar-2024
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, follow the recommended actions below.
What action should consumers take?
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the hypothalamus, pituitary gland, and adrenal gland
Review scope
Targeted
Information reviewed
ARTG Record, Labels
Issues related to safety
The name of this medicine implied that it acts on the hypothalamus and pituitary gland. This is not permitted for medicines that are available for self-selection without prior evaluation by the TGA.
However, given this medicine was never marketed in Australia, it is unlikely to pose an immediate risk to consumer health and safety.
However, given this medicine was never marketed in Australia, it is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The name of this medicine implied that it acts on the hypothalamus, pituitary gland, and adrenal gland. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The sponsor cancelled this medicine and withdrew it from further supply. Nevertheless, the TGA issued an educational letter to the sponsor outlining the issues with this medicine.